A Randomized and Blinded Multicenter Trial of High‐Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects
Top Cited Papers
Open Access
- 15 May 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (10), 1221-1228
- https://doi.org/10.1086/374850
Abstract
A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5–6 days) as therapy for candidemia due to species other than Candida krusei in adults without neutropenia. A total of 219 patients met criteria for a modified intent-to-treat analysis. The groups were similar except that those who were treated with fluconazole plus placebo had a higher mean (± standard error) Acute Physiology and Chronic Health Evaluation II score (16.8 ± 0.6 vs. 15.0 ± 0.7; P = .039). Success rates on study day 30 by Kaplan-Meier time-to-failure analysis were 57% for fluconazole plus placebo and 69% for fluconazole plus AmB (P = .08). Overall success rates were 56% (60 of 107 patients) and 69% (77 of 112 patients; P = .043), respectively; the bloodstream infection failed to clear in 17% and 6% of subjects, respectively (P = .02). In nonneutropenic subjects, the combination of fluconazole plus AmB was not antagonistic compared with fluconazole alone, and the combination trended toward improved success and more-rapid clearance from the bloodstream.Keywords
This publication has 11 references indexed in Scilit:
- Predictors of Adverse Outcome in Cancer Patients with CandidemiaAmerican Journal Of Medicine, 1998
- International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal InfectionsClinical Infectious Diseases, 1997
- Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational studyArchives of Internal Medicine, 1995
- Use of amphotericin B with azole antifungal drugs: what are we doing?Antimicrobial Agents and Chemotherapy, 1995
- Combination therapy of murine invasive candidiasis with fluconazole and amphotericin BAntimicrobial Agents and Chemotherapy, 1995
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994
- APACHE IICritical Care Medicine, 1985
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983